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Abstract
Background: Hermansky-Pudlak syndrome (HPS), a hereditary multisystem disorder with oculocutaneous albinism,
may be caused by mutations in one of at least 10 separate genes. The HPS-2 subtype is distinguished by the presence
of neutropenia and knowledge of its pulmonary phenotype in children is scarce.
Methods: Six children with genetically proven HPS-2 presented to the chILD-EU register between 2009 and 2017; the
data were collected systematically and imaging studies were scored blinded.
Results: Pulmonary symptoms including dyspnea, coughing, need for oxygen, and clubbing started 3.3 years before
the diagnosis was made at the mean age of 8.83 years (range 2-15). All children had recurrent pulmonary infections, 3
had a spontaneous pneumothorax, and 4 developed scoliosis. The frequency of pulmonary complaints increased over
time. The leading radiographic pattern was ground-glass opacities with a rapid increase in reticular pattern and traction
bronchiectasis between initial and follow-up Computer tomography (CT) in all subjects. Honeycombing and cysts were
newly detectable in 3 patients. Half of the patients received a lung biopsy for diagnosis; histological patterns were cellular
non-specific interstitial pneumonia, usual interstitial pneumonia-like, and desquamative interstitial pneumonia.
Conclusions: HPS-2 is characterized by a rapidly fibrosing lung disease during early childhood. Effective treatments
are required.
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Background
Hermansky Pudlak syndrome is a rare hereditary multi-
system disorder first described in 1959. More than 50% of
all worldwide cases are identified in individuals from
Puerto Rico where HPS has an estimated frequency of
1:1800 [1, 2]. Clinically the syndrome is characterized by
oculocutaneous albinism, a bleeding diathesis due to
platelet storage deficiency [1, 2], and other manifestations
which may include neutropenia, a granulomatous colitis,
or pulmonary fibrosis.
Genotypic analysis over the last decade allowed differen-
tiating at least 10 separate forms of HPS, due to mutations
in different genes [3]. All entities have in common defects
in intracellular protein trafficking and the biogenesis of
lysosome-related organelles like melanosomes or platelet
dense granules [2].
Pulmonary fibrosis has not been described in HPS-3
and HPS-5 through HPS-10, which are all very rare.
HPS-1 is the most common subtype and characteristic-
ally develops a severe and progressive pulmonary fibrosis
in almost all cases. Usually middle-aged adults and rarely
late adolescents are affected by fibrosis; however, so far,
children are not described [2–4]. HPS-4 has been
documented in less than 10 patients, few of which
had pulmonary fibrosis [5, 6].
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The HPS-2 subtype is also very rare, with less than 40
cases reported worldwide [4, 7–10]. HPS-2 is caused by
mutations in the AP3B1 gene, inherited in an autosomal
recessive way and distinguished from the other forms of
HPS by the presence of neutropenia that can lead to
severe respiratory infections and that is responsive to
granulocyte colony-stimulating factor [1]. Among the
few patients described, development of an interstitial
lung disease (ILD) has been mentioned in 30 to 50% [1,
7]; details on the pulmonary phenotype have been
described in four cases [4]. Potential mechanisms caus-
ing pulmonary disease in HPS-2 are poorly understood.
It has been suggested that altered AP3B1 gene product
within alveolar epithelial type II cells leads to defective
intracellular processing of surfactant proteins B and C
(SP-B, SP-C), endoplasmic reticulum-stress, apoptosis,
and a fibrotic lung phenotype [1].
The aim of this study was to describe the pulmonary
phenotype of HPS-2 in children and to further investi-
gate the presence and the possible role of cellular stress
and apoptosis in patient-derived material.
Methods
Patients, diagnosis, and follow up
Patients were recruited from the chILD-EU register and
biobank and the kids’ lung register collecting diffuse
parenchymal lung diseases [11, 12]. Among the children
included between 2009 and 2017, seven children were
diagnosed with HPS. A 0.4-year old infant with HPS-1
referred for the assessment of potential pulmonary
involvement had no pulmonary symptoms and was ex-
cluded from this study. All the other cases were HPS-2.
The diagnosis of HPS-2 was based on typical clinical
symptoms and proven by genetic analysis (Table 1).
Mutational analysis was performed by Sanger sequen-
cing. Routine clinical evaluation in different European
centers was performed; data were collected retro-
spectively and prospectively following the inclusion
into the study.
Lung function testing was done according to standards
set previously in children old enough to perform
spirometry [13]. CT images of the chest were evaluated
for the presence of parenchymal abnormalities (like
mosaic attenuation, ground glass opacity, consolidation,
linear opacity, septal thickening, reticular opacity, nodu-
lar opacity, honeycombing, emphysema, cysts, bleb or
bulla) and airway abnormalities (tree-in-bud, bronchiec-
tasis, bronchial wall thickening) on a lobar basis, count-
ing lingula as the separate lobe [14]. Also the presence
of pneumothorax, pleural thickening, pleural effusion
and enlarged hilar or mediastinal lymph node were
evaluated. The image analysis was performed blinded by
a pediatric radiologist with expertise in chest imaging.
Bronchoscopy and bronchoalveolar lavage (BAL)
Flexible Bronchoscopy including BAL (mostly of the middle
lobe) were performed if clinically indicated using 3 times
1 ml warmed normal saline per kilogram body weight. BAL
was examined cytologically and microbiologically.
Lung biopsies and histological investigations
Lung biopsies available were peer-reviewed independently
and blinded by a pathologist specialized in pulmonary
pathology. Lung tissue of patient 3 was analyzed by West-
ern blotting under reducing and denaturing conditions
using sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis followed by electroblotting and immunostaining
for pro-SP-C (Merk Millipore, Darmstadt, Germany),
ATF6, β-actin (abcam, Cambridge, UK), and cleaved
caspase-3 (Cell Signaling, Gaithersburg, USA). Blotted
membranes were developed with the ECL Plus chemilu-
minescent detection system (Amersham Biosciences,
Amersham, UK). Immunohistochemistry was performed
on lung tissue fixed in 4% formaldehyde on serial sections
with the AP Fast Red kit (Zytochem Systems, Berlin,
Germany) after antigen retrieval by microwaving in
10 mM sodium citrate buffer, pH 6.0. Hemalaun was used
as counter-stain. Slides from patient 2 were also available
for immunostaining for pro-SP-C and cleaved caspase-3,
as described above. As controls, lung sections from 3 dif-
ferent organ donor lungs were used.
Ethics, consent and permissions, consent to publish,
declarations and statement
Informed consent to report individual patient data was
obtained by all patients old enough to consent, and their
parents or guardians. The study was approved by the
ethics committee of the Ludwig-Maximilian University
of Munich (EK 111-13).
All supporting data have been entered in the additional
material (Additional file 1).
Result
Clinical course and mutations detected
The six patients included had a mean age at diagnosis of
8.83 years (Additional file 1: Detailed description of the
individual cases. Subjects 1 to 6). On average, lung
symptoms started 3.3 years before diagnosis (Table 2,
Additional file 1: Table S1). Most frequent signs and
symptoms reported at follow-up were dyspnea, cough-
ing, need for oxygen, tachypnea, and clubbing. At last
follow-up on average 3.17 years (range 2-6) after diagno-
sis, pulmonary symptoms were noted in all patients.
Overall, the frequency of all pulmonary complaints in-
creased over time. Non-pulmonary signs and symptoms
are listed in Additional file 1: Table S1.
Patients 1 and 5 were siblings and had the same homo-
zygous frameshift mutation. All other children had
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different mutations in AP3B1, two of the variations were
described before. All other mutations are likely disease-
causing mutations, as they are predicted to result in trun-
cated AP3B1 either through the introduction of a prema-
ture stop signal, by omission of a regular stop codon or by
skipping of an important structural domain for adaptor
protein 3 (AP-3 complex) formation. (Table 1, Fig. 1). Al-
though a history of consanguinity could not be obtained
in all cases, only one patient was compound heterozygous
for the mutations, supporting the autosomal recessive
Fig. 1 AP3B1 mutations and their predicted effect on protein structure. Homozygous or compound heterozygous mutations found in individuals
with HPS-2 are listed and the expected consequence for protein structure is illustrated. Colored segments represent relevant functional protein
domains and regions of altered amino acid sequence after reading frame shift (grey). Genetic nomenclature refers to the respective entries in
GenBank, NCBI. (*) NM_003664.4 (**) NG_007268.1 Abbreviations: aa = amino acid, cphet = compound heterozygous, fs = frame shift
Table 2 Pulmonary signs and symptoms at diagnosis and last follow-up
Patient 1 Patient 2 Patient 3 Patient 4 Patient
5
Patient 6 Mean (range) or
distribution (range)/
Age [y] at start of lung
symptoms
12a 2b 9d 0.8e 2 7g 5.5 (0.8-12)
Age [y] at clinical diagnosis/
last follow-up
12/ 17 9c/ 14 13/ 19 2/ 4 2/ 6 15/ 15 8.83 (2-15)/12 (4-19)
Dyspnea at diagnosis/
last follow-up
yes/ yes no/ no no/ during exercise no/ recurrent no/yes1 recurrent 1/ 5
Tachypnea at diagnosis/
last follow-up
no/ yes (32/min) no/ no (16/min) no/ no no/ yes no/ no no/ no 0/ 2
Coughing at diagnosis/
last follow-up
yes/ yes no/ no no/ during exercise no/ no no/ yes no/ no 1/ 3
Pneumothorax at diagnosis/
during course
no/ no no/ yes
(pleurodesis at
age 12 y)
no/ yes
(pleurodesis at
age 15 y)
no/ no no/ yes no/ no 0/ 3
Clubbing at diagnosis/
last follow-up
no/ no yes/ yes yes/ yes no/ no nk/ nk yes/ yes 3/ 3
Thoracic scoliosis at diagnosis/
last follow-up
no/ yes (since
age 15 y)
yes/ yes (operative
correction)
no/ yes (since age
13 y)
no/ no yes/ yes no/ no 2/ 4
Need for oxygen at diagnosis/
last follow-up
no/ no no/ yes (night time) no/no no/ recurrent yes/yesf no/ no 1/ 3
Abbreviations: y year(s), min minute, nk no known, atachypnea without cough, sputum, or cyanosis, brespiratory insufficiency and need of ventilation after birth,
recurrent pneumothoraces during childhood, cage at genetical diagnosis, dat the age of 8 clubbing revealed, dyspnea and cough during exercise at the age of 9,
erecurrent pneumonia with need of oxygen, dyspnea and fever, fwith tracheostoma, gseveral lower respiratory tract infections, clubbing revealed
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pattern of inheritance (Table 1). Of interest, 5 of 6 patients
were girls. Siblings with the same mutation had different
clinical courses. However, the small size of this cohort pre-
cludes definite conclusions about genotype-phenotype as-
sociations in patients with HPS-2.
Complications related to the respiratory tract
In 2 patients scoliosis was noticed at diagnosis, together
with psychomotor retardation. Scoliosis developed dur-
ing follow-up in 2 additional patients. In 3 patients,
spontaneous pneumothorax occurred during follow-up.
Pleurodesis was necessary for 2 patients (Table 2). In pa-
tients old enough to perform lung function testing, a
slightly impaired diffusion capacity for carbon monoxide
was noted. Initially, spirometry was in the mild abnormal
range with combined restrictive- obstructive ventilation
disorder, with changing course over time (Table 3, case de-
scriptions in Additional file 1 and Additional file 2).
Chest imaging
CT scans were performed at the time of diagnosis and at
follow-up in subjects 1, 3 and 6 (Fig. 2, Additional file 3:
Figure S1, Additional file 4: Figure S2, Additional file 5:
Figure S4, Additional file 6: Figure S5, Additional file 7:
Figure S6). For subject 4, CT was performed only at the
time of diagnosis and for subject 2 only at follow-up.
Age at first CT scan was 6.4 years (range 2.3-12) and
12.9 years (range 5.3-15.4) at follow-up. Leading radio-
graphic pattern at diagnosis was ground-glass opacity,
which had a patchy distribution, occurring in almost
each lobe in all patients. In patient 1 also reticular
opacities and traction bronchiectasis were detected at
diagnosis. Patient 3 had bronchial wall thickening in the
initial CT scan. There was a rapid increase in reticular
pattern and traction bronchiectasis between initial and
follow-up CT in all subjects with two examinations.
Honeycombing and cysts were newly detectable in 3
patients after an observation time of 5.2 years. No nodu-
lar opacity, consolidation, tree-in-bud, emphysema, or
air trapping were detected (Additional file 1: Table S2,
Fig. 2, Additional file 3: Figure S1, Additional file 4:
Figure S2, Additional file 5: Figure S4, Additional file 6:
Figure S5, Additional file 7: Figure S6). There was no
predominance of one side; upper lobes showed the most
frequent affection.
BAL and histology
Four of 6 patients had a BAL at diagnosis. One child had
very mild eosinophilia and neutrophilia. Patient 6 had
severe neutrophilia, despite peripheral blood neutropenia,
suggesting compartmentalized capacity to mobilize neutro-
phils into the alveolar space (Additional file 1: Table S3).
No pathogenic bacteria were recovered; patients were not
on antibiotic treatment at the time of diagnosis.
Table 3 Lung function measurements, lung biopsy results, treatments, and overall outcome
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Mean (n) or
distribution
Age [y] at first /
last lung function
12 / 17 nd (psychomotor
retardation)
9 / 19 nd (too young) nd (psychomotor
retardation)
8/15 9.67 / 17 (3)
FEV1 [% predicted]
first / last
74 / 71 82 / 66 63/73 73 / 70 (3)
FVC [% predicted]
first / last
65 / 70 93 / 59 62/67 73.34 / 65.34 (3)
TLC [% predicted] nd / 80 74 / 72
DLCO [% predicted]
(age at DLCO)
63 (15 y)/ 68 (17 y) 69 (15 y)/ 71
(19 y)
67.75 (4)
Lung biopsy nd cNSIP, UIP-like, DIP UIP-like nd nd cNSIP, DIP,
lymphofollicular
hyperplasia
3 biopsies
Chronic antibiotic
treatment
Co-trimoxazole Azithromycin no Azithromycin Azithromycin no 4/6
G-CSF s.c. yes yes no yes yes yes 5/6
Pirfenidone treatment yes (started age 13
for 30 months)
no yes (age 15
for 3 months)
no no no 2/6
Age last follow-up [y] 17 14 19 3.7 6 15 12.45 (range
3.7-19)
Overall outcome sick-better sick-same sick-same sick-same died sick-same 4 sick-same, 1
sick-better, 1 died
Abbreviations: y year(s), FEV1 forced expiratory volume of first second, FVC forced vital capacity, TLC total lung capacity, DLCO diffusing capacity
of the lung for carbon monoxide, cNSIP cellular non-specific interstitial pneumonitis, nd not done, UIP-like usual interstitial pneumonia- like
features, DIP desquamative interstitial pneumonitis, G-CSF granulocyte-colony stimulating factor
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Three of the 6 patients received a lung biopsy for diag-
nosis. Due to bleeding diathesis and low thrombocyte
values, thoracoscopic biopsies were performed instead of
transbronchial biopsies. In patient 2, the histological pat-
tern of cellular non-specific interstitial pneumonitis
(cNSIP), usual interstitial pneumonia- like features (UIP-
like), and of desquamative interstitial pneumonitis (DIP)
were noted and correlated to the pattern identified on
chest CT (Additional file 4: Figure S2). Patient 3 had an
UIP-like pattern of patchy dense fibrosis with subpleural
cystic areas, pleural fibrosis, and pleural blebs. Histology
showed hyperplastic and vacuolated type II pneumocytes
and ceroid containing macrophages as typical features of
HPS (see Fig. 3a-d). Patient 6 underwent lung biopsy at
the age of 6 years. Comparable to patient 2 the histological
pattern of cNSIP with areas of DIP were noted. Moreover,
lymphofollicular hyperplasia with few lymphoid follicles
was detectable. Typical vacuolated type II pneumocytes
cells were found ubiquitously but only few ceroid contain-
ing macrophages (Additional file 8: Figure S7).
Treatment
Because of neutropenia and resulting immune deficiency,
chronic antibiotic treatment in 4 and Granulocyte-Colony
Stimulating Factor, (G-CSF) treatment in 5 patients were ini-
tiated. The latter resulted in a lower normal range of
neutrophil peripheral blood counts. Pirfenidone was used in
2 patients but was stopped after 3, respectively 24 months,
due to gastrointestinal side effects and lack of sufficient
clinical improvement (Table 3).
Alveolar epithelial cellular stress and apoptosis
In patient 3 with frozen tissue available obtained from 2
different parts of the lung, additional mechanistic inves-
tigations were performed and compared to healthy tissue
obtained from unused lung of organ donors. The myofi-
broblast marker α- smooth muscle actin (SMA) was
increased in one specimen supporting increased fibrosis
(Fig. 4). Following whole lung tissue analysis, we further
analyzed type II pneumocyte apoptosis, an important
event in the pathogenesis of interstitial lung diseases.
Serial sections revealed several type II pneumocytes to
be positive for the apoptosis marker, cleaved caspase 3,
indicating their apoptosis (Fig. 3e, Additional file 4:
Figure S2H). Two types of cellular stress, the endoplas-
mic reticulum (ER) stress and autophagy can be differen-
tiated in type II pneumocytes of HPS type 1 patient
lungs [15, 16]. We thus analyzed the ER stress markers,
GRP78 and p50 form of ATF6, which were markedly in-
creased in one and moderately in the other specimen of
the lungs of the HPS-2 patient (Fig. 4). Similarly, the
autophagosomal marker microtubule-associated protein
Fig. 2 CT images of subject 3. a, b, c CT images at 8.7 years of age (column a) and follow-ups at age of 14.5 and 14.8 (column b and c). Leading
pattern is GGO on both sides at initial scan (black arrowheads) and slight increase in reticular markings (encircled) and bronchial wall thickening
(white arrowheads) at follow-up. Last follow-up showed distinctive pneumothorax and pleural effusion on the left and subpleural blebs (black
arrows) in both lung apices
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1 light chain-3β, LC3B in its lipidated form (LC3BII)
was elevated compared to two of the control lungs, one
also gave an increased signal, along with a concomitant
increase in the autophagy substrate protein, p62. This
proved a defective autophagy pathway in the lung of this
HPS-2 patient (Fig. 4a).
Discussion
Children suffering from HPS-2 may present with a severe
and progressive chronic pulmonary phenotype. Severe
lung fibrosis may develop until early adulthood; associated
complications including pneumothorax, recurrent infec-
tions, and the development of scoliosis were key features
identified. Together with few forms of ATP-binding cas-
sette sub-family A member 3 (ABCA3) [17–19], SFTPC
[20, 21], and MARS deficiency [22], this condition oper-
ates under the few clearly and rapidly fibrosing diffuse
parenchymal lung diseases in childhood.
Clinically HPS-2 in children is diagnosed by the com-
bination of albinism, bleeding diathesis, and neutropenia.
The evolution of symptoms in 4 children started with
epistaxis or bleeding diathesis as initial symptoms during
the first 2 years of life. However, respiratory symptoms
were present in all our children but obviously were rated
as too non-specific or developed too insidious to con-
tribute to the diagnosis at age 5 years. At that time, half
of our patients already had clubbing, dyspnea, and
oxygen demand. Seventeen of the 22 cases under 18 years
of age in the largest series on HPS-2 so far had respira-
tory symptoms, although not further specified [7]. Tach-
ypnea and wet coughing developed somewhat later and
suggest secondary chronic bronchitis or suppurative
lung disease. The latter may be due to additional im-
mune deficiency from neutropenia in HPS-2 subjects,
which may aggravate early respiratory affections in these
children. Three of our 6 patients developed pneu-
mothoraces, adding substantially to pulmonary morbidity.
Subpleural lung fibrosis, in particular cysts or honeycomb-
ing, predisposes to such a complication, which is very un-
usual in children at this young age. Among 4 children
with HPS-2, Gochuico et al. described one child with 6
recurrent pneumothoraces [4].
The natural history of HPS-2 lung disease differs from
that of HPS-1 pulmonary fibrosis, which usually affects
Fig. 3 Pulmonary histopathology in subject 3. a-d Histological pattern of patient 3 shows patchy dense interstitial and pleural fibrosis with
subpleural cysts/ blebs bordered by normal lung parenchyma at the right margin (c: HE × 10, d: fibrosis and cysts × 20) and small interstitial
aggregates of ceroid macrophages with pale brown pigment in the cytoplasm (arrow) as a characteristic histological finding in HPS (D × 400).
e Immunohistochemistry identifying alveolar type II cells by staining of proSP-C (SP-C), showing hyperplastic and vacuolated type II pneumocytes
as another typical feature of HPS (see also in panel d). Increase in the apoptosis marker cleaved caspase-3 in alveolar epithelial type II cells.
Representative images of immunohistochemistry for cleaved caspase-3 and proSP-C performed on serial paraffin sections of HPS-2 and organ
donor lungs. Shown here are high magnification images (40×), indicating same type II cells stained for both cleaved caspase-3 and SP-C dying
type II cells in HPS-2 patient lungs
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middle-aged adults and not children [23]. Based on pub-
lished reports, patients generally first manifest symptoms of
HPS pulmonary fibrosis in middle age, however, anecdotal
experience includes rare patients with HPS-1 beginning to
develop ILD in late adolescence [24]. Carmona-Rivera de-
scribed a 16-year-old boy with no pulmonary symptoms in
HPS-1 [25]. Characteristic pulmonary CT findings known
in adults with HPS-1 are increased reticular opacities,
thickened interlobular septa, and ground-glass infiltrates in
addition to fibrotic changes, including traction bronchiec-
tasis, subpleural cysts and honeycombing. These imaging
findings evolve over time, starting in early adulthood, as in
HPS-1 patients < 20 years usually no CT changes are noted,
in those between 20 and 29 years minimal changes were
identified, with increasing symptoms in patients 30 years
and older [26, 27]. In HPS-1, high-resolution CT abnormal-
ities inversely correlated with percentage of forced vital cap-
acity and were useful in defining the progression of
interstitial disease [27]. In our patients with HPS-2, patchy
ground-glass opacity predominated at diagnosis during
early childhood and a reticular pattern evolved rapidly over
time. At follow-up most of the children developed the CT
findings characteristic for HPS fibrosis in adults. Thus,
compared to patients with HPS-1, in HPS-2 not only pul-
monary symptoms as described above but also CT abnor-
malities were detected very early. Of interest and in
contrast to our observations, two children with HPS-2 have
been described in literature before with bilateral ground-
glass opacity, thickening of interlobular septa, and intersti-
tial reticulations (4 and 8 vs. 14 years of age) and 3 more
children suffering from HPS-2 had changes in HRCT all
with improvement over time [4, 9].
In all children, the diagnosis of HPS-2 was verified gen-
etically (Table 1). A pair of siblings had the same mutation
(patient 1 and 5), however their clinical course was differ-
ent. This was also due to the fact that the pulmonary
Fig. 4 Activation of ER-stress and autophagy in subject 3. a Western blot images showing increased expression of the endoplasmic reticulum (ER)
chaperone GRP78, ER stress marker AFT6, and importantly the p50 (cleaved form) of ATF6 in HPS-2 patient lungs. In addition, the autophagy marker
LC3B (active lipidated form is LC3BII) and SQSTM1/p62 are concomitantly increased, indicating defective autophagy in HPS-2 patient lungs (HPS-2 =
patient 3, samples from two different sites of a lung, controls = organ donors). b Representative Western blot images for the myofibroblast marker
alpha-SMA and loading control, beta-actin in lung homogenates of patient 3 (HPS-2, duplicate lanes with samples from two different sites of a lung),
and 3 different organ donors (controls, one lane each). c Increase in ER stress marker ATF6 in alveolar epithelial type II cells in HPS-2 patient lungs.
Representative images of immunohistochemistry for ATF6 and proSP-C (SP-C, alveolar epithelial type II cells marker) performed on serial paraffin
sections of HPS-2 and organ donor lungs. Shown here are low and high magnification images, using 5×, 10× and 40× objective for both HPS-2 and
donor lung sections. Far right images indicate same alveolar epithelial type II cells stained for both ATF6 and SP-C indicating many alveolar epithelial
type II cells positively stained for ATF6. Scale bar: as indicated in the images. d Control sections represent ATF6 and SP-C stainings in donor lung
sections, where almost no ATF6 is detected in SP-C positive alveolar epithelial type II cells
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phenotype of the second child was much more and earlier
in focus after the other died. A frameshift mutation in the
C-terminal region of AP3B1 resulted in loss of the stop
codon, prolonging translation into the 3’UTR region. Al-
though an alternative in-frame stop codon is available fur-
ther downstream, increased distance to the original stop
codon may predispose transcripts to nonstop-mediated
decay mechanisms [28]. Alternatively, the translated pro-
tein product might be subject to proteolytic breakdown
due to misfolding, defective assembly, or intrinsic con-
formational instability [29]. Patient 2 displayed a larger
genomic deletion which includes parts of introns 14, 15,
and exon 15. This specific region has shown to be essen-
tial for correct assembly of the AP3-complex [30]. In all
other individuals, single point mutations (patient 3) or
frameshift mutations caused by base pair deletions about
10-120 base pairs upstream (patient 4, 6) lead to prema-
ture stop codons, translation termination, and possibly ac-
tivation of the nonsense-mediated decay pathway (Fig. 1).
The pulmonary fibrosis in patients with HPS may be
preceded by a macrophage-mediated alveolar inflamma-
tion, as BAL fluid contains increased numbers of constitu-
tively activated macrophages [26]. Only one of the
subjects with BAL had increased macrophage counts
(Additional file 1: Table S3). All our patients had progres-
sively fibrosing lung disease already during childhood.
Our histological data prove that pulmonary fibrosis affects
children with HPS-2. This is in contrast to HPS-1 and 4,
where the development of pulmonary fibrosis starts in
middle-age adults and children are only rarely affected
[24]. Overall rapidly progressive fibrosing lung disease in
childhood is extremely rare. The development of fibrosis
might be facilitated by the patients’ neutropenia and
natural killer - and T-cell dysfunction and the resulting
susceptibility to severe recurrent chest infections. Such an
observation is consistent with the HPS-2 animal model
where environmental lung injury by silica or bleomycin
aggravates fibrosis [26]. Therefore, preventive measures as
vaccination and aggressive antibiotic treatment are war-
ranted. Taking our limited observation length into ac-
count, the clinical course was not stable in most children.
Despite intense symptomatic treatments after diagnosis,
we saw deterioration and development of complications in
several patients. Four patients remained unchanged, one
patient improved, one patient (subject 5), however, died
from respiratory insufficiency.
The histology of HPS-2 interstitial lung disease is not
widely explored, as the diagnosis may now be done gen-
etically. Patient 2 had a combination of NSIP and UIP-
like pattern with dense fibrosis in peribronchiolar and
subpleural distribution, as well as a DIP- like areas with
intraalveolar aggregates of alveolar macrophages, very
similar to other descriptions published [4]. Lung biopsy
of patient 3 was dominated by a patchy dense fibrosis
with UIP-like pattern comparable to patient 2. Lung
biopsy of patient 6 did not show areas of dense fibrosis
but demonstrated a cellular NSIP pattern. Additionally,
there was a mild lymphoid hyperplasia with few lymph-
oid follicles with germinal centers that could probably
be interpreted as post-infectious changes.
Apoptosis of type II pneumocytes, in addition to ER
stress and defective autophagy, was observed in a HPS-2
patient lung. This finding is in line with the previously
reported observations of cellular stress and apoptosis of
type II pneumocytes in several interstitial lung diseases.
More studies are needed to determine if defective au-
tophagy or ER stress underlie type II pneumocyte apop-
tosis and are subsequently responsible for fibrotic
remodeling in the HPS-2 patient lung.
Conclusion
We highlight that patients with HPS-2 in contrast to the
other forms of HPS must be considered a severely and
rapidly fibrosing lung disease already during early child-
hood which requires effective antifibrotic treatment. The
latter is not yet available in childhood. At diagnosis, half
of the subjects had clinical signs of chronic hypoxemia.
Histology remains of importance in those extreme rare
diseases, which should be made based on the clinical
phenotype and confirmed by targeted genetics. During
the course, which may be complicated by recurrent
pneumothoraces and scoliosis, a comprehensive multi-
disciplinary team approach is needed. Currently early
symptomatic pulmonary care including consequent anti-
biotic treatment of pulmonary infections and vaccina-
tions. Nutritional management and early orthopedic
treatment of scoliosis may help to improve the outcome
of children with HPS-2. No specific antifibrotic treat-
ment is available in children.
Additional files
Additional file 1: Detailed description of the individual cases. Subjects 1
to 6. Table S1. Non-pulmonary signs and symptoms. Table S2. Blinded
scoring of CT-scans (number of CTs available at diagnosis (n = 5)/ at
follow-up (n = 5); CTs at follow-up and diagnosis available in sub 1-3 and
6, only at follow-up in sub. 2 and only at diagnosis in sub. 4). Scans were
analysed for the presence and absence of features listed in the six
sections of the lungs. Scoring was not validated. Table S3. Results of
bronchoalveolar lavage (BAL) at diagnosis. (DOC 107 kb)
Additional file 2: Figure S3. Bodyplethysmography of subject 3.
Bodyplethysmography at the last follow up (19 years of age). Visible is
the restrictive pattern with mild obstruction. (TIFF 807 kb)
Additional file 3: Figure S1. CT scan and spirometry course of subject 1.
(A) CT scan at 12 and 15 years of age. Initially patchy GGO (black
arrowheads) and mild reticulations were seen in all lobes with apical
predominance, at follow-up also reticular pattern increased and traction
bronchioloectasis and mild honeycombing appeared (black arrows). (B)
Spirometry long-term course of FVC which shows variabilities of 15%
during the last 4 years. Pirfenidone treatment led to improvement first, but
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had no effect during long term course. First bodyplethysmographia was
performed at 13 years of age, last one at the age of 17 years. (TIFF 3981 kb)
Additional file 4: Figure S2. CT scan and histological pattern of subject 2.
(A) CT scan at the age of 13 8/12 years. CT images show the thorax
deformity due to scoliosis with displacement of the central bronchial
structures and traction of the segmental bronchi. On the left side, cystic
parenchymal destruction in the apex (black arrow), mild bronchial wall
thickening in the upper lobe (encircled), reticular opacities predominantly
in the upper lobe and lingula. Increased lung density especially in the
lower lobe is due to breathing artefacts and areas of ground-glass opacity.
On the right side, there are few subpleural cysts in the apex and reticular
opacities in the upper and middle lobe. (B-G) Histological pattern with
patchy areas of dense interstitial fibrosis (red) in peribronchiolar and
subpleural distribution (B: HE, x10). Dense fibrosis with small areas of
honeycombing with bronchiolar metaplasia (C: HE, x50). Fibroblastic foci
as features of UIP pattern (D: HE, x 200) and areas with NSIP pattern
consisting of diffuse mild interstitial fibrosis and a mild chronic
inflammatory infiltrate in between (E: HE, x100). Few small interstitial
aggregates of ceroid macrophages (F: HE, x200) and vacuolization of
hyperplastic type II pneumocytes (G: HE, x400) as subtle but characteristic
features of HPS (G). (H) Increase in the apoptosis marker cleaved caspase-3
in alveolar epithelial cells type II (AECII) in HPS2 patient lungs. Representative
images of immunohistochemistry for cleaved caspase-3 and proSP-C (AECII
marker) performed on serial paraffin sections of HPS2 and organ donor lungs.
Shown here are high magnification images, 40x objective for both HPS2 and
donor lung sections. Arrows indicate same AECII stained for both cleaved
caspase-3 and SP-C implying dying AECII in HPS2 patient lungs while almost
no cleaved caspase-3 is detected in SP-C positive AECII of donor lungs. Scale
bar: as indicated in the images. (TIFF 4239 kb)
Additional file 5: Figure S4. CT scan of subject 4. CT Scan with patchy
distribution of ground glass opacity throughout all lobes. (JPEG 8908 kb)
Additional file 6: Figure S5. CT scan of subject 5. CT at 2 (left column)
and 5 (right column) years of age. Initial scan was performed in prone
position, follow up in supine position. Initial scan demonstrates linear
opacities (black arrows) with mild traction bronchiectasis. After a course
of 3 years CT scan deteriorates with severe parenchymal abnormalities
showing diffuse ground glass opacity, reticular opacity, mild
honeycombing, and cysts (black arrowheads). Moreover enlarged
mediastinal und hilar lymph nodes have been seen (better seen on the
mediastinal window, images not provided here). (TIFF 7675 kb)
Additional file 7: Figure S6. CT scan of subject 6. CT images at 6
(first column), 9 (second column), 11 (third column) and 15
(fourth column) years of age. At the initial scan subject presented with
patchy GGO in all lobes and additional interlobular septal thickening
(encircled in white). At first follow up, a decrease of GGO in the left
upper and lower lobes can be seen (black arrows in initial scan, first
column). Over the next years, the distribution and extent of GGO showed
no relevant changes. The extents of interlobular septal thickening
decreased at the first follow up, followed by increase of reticular
markings (encircled in black) in the next scans. Also bronchial wall
thickening was present on the last follow up scans, here best seen in the
right lower lobe in the third column (dashed circle). (TIFF 4655 kb)
Additional file 8: Figure S7. Histological pattern of subject 6. A
(HE, x50): Normal lung architecture with partly collapsed alveolar spaces
on the right containing aggregates of alveolar macrophages (Black arrows).
Hypercellular interstitium with diffuse mild lymphocytic infiltrate in alveolar
septa and few lymphoid follicles. B (HE, x100): Prominent lymphoid follicle
with central germinal center, interstitial lymphocytes and intraalveolar
macrophages. C (HE, x200): Aggregates of intraalveolar macrophages with
pink cytoplasm (black arrows), interstitial lymphocytes with small blue nuclei
(black triangles), scattered type II pneumocytes with clear vacuolated
cytoplasm (white arrows) typically found in HPS. (TIFF 5371 kb)
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